Incyte announced that the first patient has been treated in the Phase 3 TRuE-AD clinical trial program evaluating the long-term safety and efficacy of ruxolitinib cream as monotherapy for adolescent and adult patients with atopic dermatitis, or AD, who are candidates for topical therapy. The TRuE-AD clinical trial program includes two Phase 3 studies evaluating the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis. The primary endpoint of the TRuE-AD studies is the proportion of participants achieving an investigator’s global assessment treatment success, or IGA-TS, defined as an IGA score of 0 or 1 with at least a two-point improvement from baseline at week 8.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.